文献速递淋巴瘤

免疫化疗后达EFS24的DLBCL患者晚期复发率与结局

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
PubMed 文献 · J Clin Oncol · 2019-06-06

研究前瞻性随访2002至2015年接受免疫化疗的1324例新诊断DLBCL患者,分析达EFS24后晚期复发累积发生率及复发后生存。847例达EFS24者晚期复发累积发生率3年6.9%、5年9.3%、8年10.3%;合并惰性淋巴瘤者惰性淋巴瘤复发率更高,GCB亚型惰性淋巴瘤复发率更高;DLBCL复发者复发后生存劣于惰性淋巴瘤复发者。

要点

  • 达EFS24后晚期复发累积发生率8年为10.3%。
  • 合并惰性淋巴瘤者5年惰性淋巴瘤复发率7.4% vs 2.1%(P<.01)。
  • DLBCL复发者复发后生存劣于惰性淋巴瘤复发者(中位29.9个月 vs 未达到;P<.01)。

核心结论

  • 合并惰性淋巴瘤的DLBCL患者和GCB亚型患者晚期复发率更高,归因于惰性淋巴瘤复发增加;DLBCL复发者预后劣于惰性淋巴瘤复发者。

研究设计与样本

  • 前瞻性随访2002至2015年新诊断DLBCL并接受免疫化疗的患者1324例,分析达EFS24后晚期DLBCL和惰性淋巴瘤复发的累积发生率(竞争事件分析),复发后生存定义为首次复发至任何原因死亡的时间。

主要发现

  • 847例达EFS24患者中,晚期复发累积发生率在EFS24后3年为6.9%、5年为9.3%、8年为10.3%。
  • 诊断时单纯DLBCL患者5年DLBCL复发率6.3%,合并惰性淋巴瘤患者5.2%(P=.46)。
  • 合并惰性淋巴瘤患者5年惰性淋巴瘤复发率7.4% vs 单纯DLBCL患者2.1%(P<.01)。
  • 单纯DLBCL患者中,GCB亚型5年DLBCL复发率4.1% vs 非GCB亚型4.0%(P=.71);GCB亚型5年惰性淋巴瘤复发率3.9% vs 非GCB亚型0.0%(P=.02)。
  • DLBCL复发者复发后生存中位29.9个月 vs 惰性淋巴瘤复发者未达到(P<.01)。

临床怎么用

  • 达EFS24的DLBCL患者仍需关注晚期复发,尤其合并惰性淋巴瘤及GCB亚型者。
  • 晚期复发类型影响预后,DLBCL复发者复发后生存较差。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS: We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS: In 847 patients who achieved EFS24, the cumulative incidence of late relapse was 6.9% at 3 years, 9.3% at 5 years, and 10.3% at 8 years after EFS24. The incidence of DLBCL relapse was similar in patients with DLBCL alone at diagnosis (6.3% at 5 years), compared with patients with concurrent indolent lymphoma at diagnosis (5.2%; P = .46). However, the rate of indolent lymphoma relapse was higher in patients with concurrent indolent lymphoma (7.4% v 2.1% at 5 years; P < .01). In patients with DLBCL alone, the rate of DLBCL relapse was similar in the germinal center B-cell-like (GCB) (4.1% at 5 years) and non-GCB (4.0%; P = .71) subtypes, whereas the rate of indolent lymphoma relapse was higher in patients with the GCB subtype (3.9% v 0.0% at 5 years; P = .02). Postrelapse survival was inferior for patients who relapsed with DLBCL than for those who relapsed with indolent lymphoma (median 29.9 months v unreached; P < .01). CONCLUSION: Patients with DLBCL with a concurrent indolent lymphoma and those with the GCB subtype had a higher rate of late relapse, owing to increased relapses with indolent lymphoma. Patients who relapsed with DLBCL had a worse prognosis than those who relapsed with indolent lymphoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Farooq U, Link BK, et al. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2019. PMID: 31170029. doi:10.1200/JCO.19.00014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。